See more : Culpeo Minerals Limited (CPORF) Income Statement Analysis – Financial Results
Complete financial analysis of Catalyst Pharmaceuticals, Inc. (CPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catalyst Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RenetJapanGroup,Inc. (3556.T) Income Statement Analysis – Financial Results
- Sierra Rutile Holdings Limited (SRX.AX) Income Statement Analysis – Financial Results
- Bowen Acquisition Corp (BOWN) Income Statement Analysis – Financial Results
- TerrAscend Corp. (TSND.TO) Income Statement Analysis – Financial Results
- Asia Medical and Agricultural Laboratory and Research Center Public Company Limited (AMARC.BK) Income Statement Analysis – Financial Results
Catalyst Pharmaceuticals, Inc. (CPRX)
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 398.20M | 214.20M | 140.83M | 119.07M | 102.31M | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 84.53M | 34.39M | 21.88M | 17.04M | 14.76M | 19.92M | 45.69K | 43.41K | 34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 313.67M | 179.81M | 118.95M | 102.03M | 87.55M | -19.42M | -45.69K | -43.41K | -34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.77% | 83.94% | 84.46% | 85.69% | 85.57% | -3,883.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.15M | 19.79M | 16.94M | 16.50M | 18.84M | 19.92M | 11.38M | 11.37M | 11.80M | 10.12M | 8.10M | 2.66M | 3.38M | 2.31M | 5.10M | 8.71M | 2.99M | 989.14K | 1.46M | 378.25K | 0.00 | 137.68K |
| General & Administrative | 47.02M | 28.71M | 23.48M | 20.67M | 33.58M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 86.69M | 29.47M | 26.15M | 23.57M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.71M | 58.18M | 49.63M | 44.23M | 36.88M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 2.04M | 1.91M | 359.28K | 164.70K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -428.62K | 118.27K |
| Operating Expenses | 259.43M | 77.97M | 66.56M | 60.73M | 55.72M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Cost & Expenses | 311.39M | 112.37M | 88.45M | 77.77M | 70.48M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Interest Income | 0.00 | 0.00 | 282.00K | 587.00K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 32.88M | 1.49M | 484.00K | 885.32K | 297.73K | 37.98K | 45.69K | 43.41K | 34.47K | 26.57K | 22.48K | 10.89K | 42.84K | 25.74K | 30.23K | 32.76K | 15.76K | 4.93K | 1.37K | 366.00 | 0.00 | 0.00 |
| EBITDA | 119.69M | 101.84M | 52.39M | 41.30M | 31.82M | -35.26M | -18.49M | -18.03M | -20.46M | -13.57M | -8.40M | -6.35M | -6.35M | -4.00M | -7.21M | -10.53M | -5.01M | -2.72M | -1.82M | -542.59K | -428.62K | -255.95K |
| EBITDA Ratio | 30.06% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -817.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 86.81M | 101.84M | 52.39M | 41.30M | 31.82M | -35.30M | -18.68M | -19.28M | -20.40M | -14.59M | -10.31M | -5.22M | -6.08M | -4.02M | -7.28M | -10.89M | -5.03M | -2.90M | -1.82M | -542.96K | -428.62K | -255.95K |
| Operating Income Ratio | 21.80% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -823.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.70M | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 267.26K | 1.21M | 165.39K | -917.63K | -1.84M | 1.14M | -308.92K | 17.86K | 33.47K | 329.35K | 887.64K | 172.87K | 16.79K | 3.14K | 0.00 | 0.00 |
| Income Before Tax | 94.51M | 104.72M | 52.67M | 41.89M | 33.41M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | 0.00 | -255.95K |
| Income Before Tax Ratio | 23.73% | 48.89% | 37.40% | 35.18% | 32.66% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 23.10M | 21.64M | 13.19M | -33.09M | 1.53M | 2.58M | 141.22K | -929.54K | -99.47K | 993.87K | 1.84M | -1.16M | 308.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 428.62K | 0.00 |
| Net Income | 71.41M | 83.08M | 39.48M | 74.98M | 31.88M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | -428.62K | -255.95K |
| Net Income Ratio | 17.93% | 38.79% | 28.03% | 62.97% | 31.16% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.67 | 0.80 | 0.38 | 0.72 | 0.31 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| EPS Diluted | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| Weighted Avg Shares Out | 106.28M | 103.37M | 103.38M | 103.51M | 102.94M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
| Weighted Avg Shares Out (Dil) | 113.75M | 111.38M | 107.80M | 106.24M | 106.02M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of...
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public offering of $150,000,000 of its common stock. Catalyst also intends to grant the...
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is Catalyst Pharmaceuticals (CPRX) Stock a Solid Choice Right Now?
Catalyst Pharmaceuticals (CPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized companies have also rallied, but not as much:
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its collaboration partner, DyDo Pharma,...
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital ecosystem, society will continue to invest in clinical breakthrough stocks in...
Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024.
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CORAL GABLES,...
Source: https://incomestatements.info
Category: Stock Reports